期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 87, 期 1, 页码 130-133出版社
WILEY
DOI: 10.1038/clpt.2009.197
关键词
-
资金
- Helsinki University Central Hospital Research Fund (Helsinki, Finland)
- Sigrid Juselius Foundation (Helsinki, Finland)
Polymorphisms in transporter genes can have profound effects on statin pharmacokinetics. In particular, a common genetic variant of organic anion-transporting polypeptide 1B1 reduces the hepatic uptake of many statins, increasing the risk of statin-induced myopathy. Similarly, genetically impaired adenosine triphosphate (ATP)-binding cassette G2 transporter efflux activity results in a marked increase in systemic exposure to various statins. Importantly, the effects of these genetic polymorphisms differ depending on the specific statin that is used. This provides a rational basis for the individualization of lipid-lowering therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据